New York, United States
Neurogene Inc., founded in 2018, is making significant strides in the Biotechnology sector by developing genetic medicines aimed at treating rare neurological diseases. With the slogan "Reimagining the future for rare neurological diseases," the company is on a mission to address unmet medical needs in the field of neurology.
Neurogene is advancing a comprehensive pipeline of therapies designed to treat the root causes of serious neurological disorders, targeting conditions that have long been underserved. The company leverages the ongoing genomics revolution to bring to market innovative solutions that improve the lives of children with neurological impairments and provide hope to their families.
The latest financial milestone for Neurogene is a recent private placement investment of $200.00M on 01 November 2024. This round was supported by prominent investors including Casdin Capital, Redmile Group, Commodore Capital, EcoR1 Capital, RTW Investments, Samsara BioCapital, and Great Point Partners, underscoring substantial confidence in the company's potential and growth. Neurogene's commitment to innovation could position it as a key player in the genetics-based treatment landscape.
